# Zylox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zylox

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.zyloxmedical.com
- Total disclosed funding: $45M
- Latest round: Series C (Oct 30, 2020)
- Investors on record: 4

## About

Established in 2012 and based in Hangzhou, China, Zylox operates as a medical device company dedicated to providing cardiovascular medical devices. It has sub-branch offices in Zhuhai, Beijing, and Shanghai. The company has obtained 35 utility model patents and 9 invention patents. The chairman, founder, and CEO of the company, Zhong Zhao graduated from Johns Hopkins University. In June 2021, Zylox raised USD 145 million in pre-IPO funding. In July 2021, Zylox was listed on the Hong Kong Stock Exchange.

The company mainly provides two product platforms, which are peripheral vascular intervention solution product platform and neurovascular intervention solution full product platform. The main products of peripheral vascular intervention platform are peripheral vascular stent system and PTA balloon dilation catheter. Zylox also provides products in categories such as balloons, stents, accessories, embolization agents, etc. The company has 57 products under research, of which 34 products have been approved for market by NMPA. Zylox is currently expanding into new therapeutic areas, including vascular closure devices.

In 2022, the company's revenue was CNY 334.09 million.

## Funding rounds

- Series C, Oct 30, 2020, $45M — OrbiMed Advisors, Zheshang Venture Capital, HighLight Capital, SDIC Fund Management
- Series B, Jan 19, 2019 — SDIC Fund Management

## Investors

- SDIC Fund Management (https://capitalatlas.ai/funds/sdic-fund-management) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C